DK2675893T3 - Dirigeret differentiering af oligodendrocyt-præcursorceller til en myeliniseringscelleskæbne - Google Patents

Dirigeret differentiering af oligodendrocyt-præcursorceller til en myeliniseringscelleskæbne Download PDF

Info

Publication number
DK2675893T3
DK2675893T3 DK12747134.0T DK12747134T DK2675893T3 DK 2675893 T3 DK2675893 T3 DK 2675893T3 DK 12747134 T DK12747134 T DK 12747134T DK 2675893 T3 DK2675893 T3 DK 2675893T3
Authority
DK
Denmark
Prior art keywords
agent
benztropine
neurotransmitter receptor
neurotransmitter
immunomodulatory agent
Prior art date
Application number
DK12747134.0T
Other languages
English (en)
Inventor
Peter Schultz
Vishal Deshmukh
Costas Lyssiotis
Luke Lairson
Original Assignee
Scripps Research Inst
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst, Novartis Ag filed Critical Scripps Research Inst
Application granted granted Critical
Publication of DK2675893T3 publication Critical patent/DK2675893T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Claims (15)

1. Neurotransmitterreceptor-modulerende middel til anvendelse i en fremgangsmåde til stimulering af øget myelinisering af nerver hos et menneske med en demyelinisationssygdom, hvilken fremgangsmåde omfatter administration til individet af en terapeutisk virksom dosis af det neurotransmitterreceptor-modulerende middel, hvor midlet er en muscarinreceptorantagonist.
2. Neurotransmitterreceptor-modulerende middel til anvendelsen ifølge krav 1, hvor muscarinreceptorantagonisten er benztropin, carbetapentan, clemastin, ipratropium, atropin, oxybutynin, propiverin, scopolamin eller et salt deraf.
3. Neurotransmitterreceptor-modulerende middel til anvendelsen ifølge krav 1 eller 2, hvor fremgangsmåden endvidere omfatter administration til individet af et immunmodulerende middel.
4. Neurotransmitterreceptor-modulerende middel til anvendelse i en fremgangsmåde til forbedring af den terapeutiske virkning af et immunmodulerende middel i behandlingen af en demyelinisationssygdom, hvilken fremgangsmåde omfatter administration til et menneske med demyelinisationssygdommen af det immunmodulerende middel og det neurotransmitterreceptor-modulerende middel, hvor det neurotransmitterreceptor-modulerende middel er en muscarinreceptorantagonist.
5. Neurotransmitterreceptor-modulerende middel til anvendelsen ifølge krav 4, hvor: muscarinreceptorantagonisten er benztropin, clemastin, carbetapentan, ipratropium, atropin, oxybutynin, propiverin, scopolamin, eller et salt deraf.
6. Neurotransmitterreceptor-modulerende middel til anvendelsen ifølge krav 4 eller krav 5, hvor: (a) hvert af det immunmodulerende middel og det neurotransmitterreceptor-modulerende middel administreres ved en terapeutisk virksom dosis; (b) det neurotransmitterreceptor-modulerende middel administreres ved en terapeutisk virksom dosis og det immunmodulerende middel administreres ved en subterapeutisk dosis; (c) hvert af det immunmodulerende middel og det neurotransmitterreceptor-modulerende middel administreres ved en subterapeutisk dosis; (d) det immunmodulerende middel og det neurotransmitterreceptor-modulerende middel administreres systemisk; (e) det immunmodulerende middel og det neurotransmitterreceptor-modulerende middel administreres sekventielt; eller (f) det immunmodulerende middel og det neurotransmitterreceptor-modulerende middel administreres samtidigt.
7. Sammensætning til anvendelse i behandling af et individ med en demyelinisationssygdom, hvilken sammensætning omfatter: en muscarinreceptorantagonist og et immunmodulerende middel.
8. Sammensætning ifølge krav 7, hvor: muscarinreceptorantagonisten er benztropin, clemastin, carbetapentan, ipratropium, atropin, oxybutynin, propiverin, scopolamin eller et salt deraf.
9. Sammensætning ifølge krav 7 eller krav 8, hvor: (a) hvert af det immunmodulerende middel og det neurotransmitterreceptor-modulerende middel er formuleret som en terapeutisk virksom dosis; (b) det neurotransmitterreceptor-modulerende middel er formuleret som en terapeutisk virksom dosis og det immunmodulerende middel er formuleret som en subterapeutisk dosis; eller (c) hvert af det immunmodulerende middel og det neurotransmitterreceptor-modulerende middel er formuleret som en subterapeutisk dosis.
10. Kit til anvendelse i behandling af et individ med en demyelinisationssygdom, hvilket kit omfatter: en muscarinreceptorantagonist og et immunmodulerende middel.
11. Kit ifølge krav 10, hvor: muscarinreceptorantagonisten er benztropin, clemastin, carbetapentan, ipratropium, atropin, oxybutynin, propiverin, scopolamin eller et salt deraf.
12. Kit ifølge krav 10 eller krav 11, hvor: (a) hvert af det immunmodulerende middel og det neurotransmitterreceptor-modulerende middel er formuleret som en terapeutisk virksom dosis; (b) det neurotransmitterreceptor-modulerende middel er formuleret som en terapeutisk virksom dosis og det immunmodulerende middel er formuleret som en subterapeutisk dosis; (c) hvert af det immunmodulerende middel og det neurotransmitterreceptor-modulerende middel er formuleret som en subterapeutisk dosis; (d) det neurotransmitterreceptor-modulerende middel og det immunmodulerende middel er i den samme formulering; eller (e) det neurotransmitterreceptor-modulerende middel og det immunmodulerende middel er i separate formuleringer.
13. Neurotransmitterreceptor-modulerende middel til anvendelsen ifølge et hvilket som helst af krav 1 to 3, sammensætning ifølge krav 7, eller kit ifølge krav 10, hvor demyelinisationssygdommen er multipel sklerose, idiopatisk inflammatorisk demyelinisationssygdom, transversel myelitis, Devics sygdom, progressiv multifokal leukoencephalopati, optisk neuritis, leukodystrofi, Guillain-Barre-syndrom, kronisk inflammatorisk demyeliniserende polyneuropati, autoimmun perifer neuropati, Charcot-Marie-Tooth-sygdom, akut dissemineret encephalomyelitis, adrenoleukodystrofi, adrenomyeloneuropati, Lebers hereditære opticus neuropati eller HTLV-associeret myelopati.
14. Neurotransmitterreceptor-modulerende middel til anvendelsen ifølge et hvilket som helst af krav 3 til 5, sammensætning ifølge krav 7 eller krav 8, eller kit ifølge krav 10 eller krav 11, hvor det immunmodulerende middel er fingolimod (FTY720), interferon beta-la, interferon beta-lb, glatiramer-acetat, mitoxantron eller natalizumab.
15. Neurotransmitterreceptor-modulerende middel til anvendelsen ifølge et hvilket som helst af krav 3 til 5, sammensætning ifølge krav 7 eller krav 8, eller kit ifølge krav 10 eller krav 11, hvor det immunmodulerende middel er en S1P-agonist.
DK12747134.0T 2011-02-18 2012-02-17 Dirigeret differentiering af oligodendrocyt-præcursorceller til en myeliniseringscelleskæbne DK2675893T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161444666P 2011-02-18 2011-02-18
PCT/US2012/025712 WO2012112933A1 (en) 2011-02-18 2012-02-17 Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate

Publications (1)

Publication Number Publication Date
DK2675893T3 true DK2675893T3 (da) 2019-04-15

Family

ID=46672968

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12747134.0T DK2675893T3 (da) 2011-02-18 2012-02-17 Dirigeret differentiering af oligodendrocyt-præcursorceller til en myeliniseringscelleskæbne

Country Status (6)

Country Link
US (4) US9592288B2 (da)
EP (2) EP2675893B1 (da)
JP (3) JP6133790B2 (da)
DK (1) DK2675893T3 (da)
ES (1) ES2716865T3 (da)
WO (1) WO2012112933A1 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2675893B1 (en) 2011-02-18 2019-01-09 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
CA2838486A1 (en) * 2011-08-07 2013-02-14 Kadimastem Ltd. Method of identifying agents that affect maturation, survival and myelination
EP2724723A1 (en) * 2012-10-25 2014-04-30 Universitätsklinikum Hamburg-Eppendorf Tegaserod for use in the treatment of nerve injuries
EP2943189B1 (en) * 2013-01-08 2021-03-10 Pathologica LLC Mitoguazone for treatment of progressive multiple sclerosis
WO2014138298A1 (en) * 2013-03-05 2014-09-12 University Of Chicago Treatment of demyelinating disorders
CN105143174B (zh) * 2013-03-15 2021-01-12 苏州泰飞尔医药有限公司 治疗帕金森疾病的新型高穿透力药物及其药物组合物
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
PL3082845T3 (pl) * 2013-12-20 2021-08-02 University Of Manitoba Sposoby i kompozycje do leczenia neuropatii obwodowych
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
FR3029113A1 (fr) * 2014-12-02 2016-06-03 Univ Paris-Sud Composes pour le traitement des maladies mitochondriales
EP3118621A1 (en) * 2015-07-14 2017-01-18 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Methods and compositions for the diagnosis and for the treatment of adrenoleukodystrophy
MD3344248T2 (ro) * 2015-09-02 2022-10-31 Trevena Inc Aza-heterociclic cu 6 elemente conținând compuși de modulare a receptorului delta-opioid, metode de utilizare și fabricare a acestora
CN107286031B (zh) * 2016-04-05 2019-08-09 上海医药工业研究院 2-二乙氨基-1-甲基乙基-7-环己基-7-氧庚酸酯的制备方法
EP3538115A4 (en) * 2016-11-14 2020-04-22 Memorial Sloan Kettering Cancer Center STEM CELL-DERIVED SWAN CELLS
US11702408B2 (en) 2017-02-17 2023-07-18 Trevena, Inc. 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
EP3582783B1 (en) 2017-02-17 2023-06-07 Trevena, Inc. 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
SG11201909501TA (en) * 2017-04-13 2019-11-28 Univ Leland Stanford Junior Personalized 3d neural culture system for generating human oligodendrocytes and studying myelination in vitro
US11478467B2 (en) * 2017-05-04 2022-10-25 Sreenivasarao Vepachedu Targeted drug rescue with novel compositions, combinations, and methods thereof
EP3412294A1 (en) * 2017-06-08 2018-12-12 Universite De Fribourg Hdac1/2 activator for promoting and/or accelerating myelination and/or remyelination
AU2019229892A1 (en) 2018-03-08 2020-09-03 University Of Kansas Treatment of demyelinating diseases
WO2019172969A1 (en) * 2018-03-08 2019-09-12 The Scripps Research Institute Methods for promoting myelination and for treating demyelinating diseases
AU2019247871A1 (en) * 2018-04-05 2020-10-15 Frequency Therapeutics, Inc. Compositions and methods for increasing remyelination
MX2020010829A (es) * 2018-04-13 2021-03-25 Mordechai Chevion Composiciones y metodos para el tratamiento de la desmielinización.
CN108624560B (zh) * 2018-06-01 2022-04-08 南京艾尔普再生医学科技有限公司 一种分化培养基及少突胶质前体细胞的制备方法
EP3806957A4 (en) * 2018-06-14 2022-03-16 Curasen Therapeutics, Inc. METHODS FOR DIAGNOSING, MONITORING AND TREATING NEUROLOGICAL DISEASES AND DISORDERS
CN111317754B (zh) * 2018-12-13 2022-02-18 泰州医药城国科化物生物医药科技有限公司 一种北豆根总碱的制备方法及应用
CN109942592B (zh) * 2019-05-09 2020-07-14 江西中医药大学 一种新原阿片碱型生物碱及其制备方法和应用
EP3797769A1 (fr) * 2019-09-25 2021-03-31 Fontès, M. Michel Composition a usage therapeutique
AU2022275912A1 (en) * 2021-05-21 2024-01-18 Chengdu Wending Technology Development Co., Ltd Method for modulating neuropathies
WO2023225206A1 (en) 2022-05-18 2023-11-23 The Scripps Research Institute Method for enhancing remyelination via co-administration of muscarinic receptor antagonists and vitamin d analogues
CN117599054B (zh) * 2024-01-24 2024-03-29 成都第一制药有限公司 一种治疗假性近视的药物组合物及其用途

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4933438A (en) 1984-02-29 1990-06-12 University Of Florida Brain-specific analogues of centrally acting amines
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US6150354A (en) 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
ATE183084T1 (de) 1991-05-14 1999-08-15 Ernir Snorrason Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren
IT1250421B (it) 1991-05-30 1995-04-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5264459A (en) * 1992-07-13 1993-11-23 Arch Development Corporation Use of β-adrenergic agonists to treat patients with demyelinating or autoimmune diseases
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
FR2710265B1 (fr) 1993-09-22 1995-10-20 Adir Composition pharmaceutique bioadhésive pour la libération contrôlée de principes actifs.
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US6548084B2 (en) 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
US6245347B1 (en) 1995-07-28 2001-06-12 Zars, Inc. Methods and apparatus for improved administration of pharmaceutically active compounds
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
DE19541260A1 (de) 1995-11-06 1997-05-07 Lohmann Therapie Syst Lts Therapeutische Zubereitung zur transdermalen Applikation von Wirkstoffen durch die Haut
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
JPH10218867A (ja) 1997-02-10 1998-08-18 Pola Chem Ind Inc ドーパミン再取り込み阻害剤
EP1017370B1 (en) 1997-09-11 2003-10-29 Nycomed Danmark ApS MODIFIED RELEASE MULTIPLE-UNITS COMPOSITIONS OF NON-STEROID ANTI-INFLAMMATORY DRUG SUBSTANCES (NSAIDs)
US6624200B2 (en) 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6607751B1 (en) 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6248864B1 (en) 1997-12-31 2001-06-19 Adherex Technologies, Inc. Compounds and methods and modulating tissue permeability
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
JP2002519373A (ja) * 1998-07-02 2002-07-02 エーザイ株式会社 製薬組成物及びそれらの使用
US6312717B1 (en) 1998-07-07 2001-11-06 Bristol-Myers Squibb Company Method for treatment of anxiety and depression
US20020009478A1 (en) 1998-08-24 2002-01-24 Douglas Joseph Dobrozsi Oral liquid mucoadhesive compositions
SE9802864D0 (sv) 1998-08-27 1998-08-27 Pharmacia & Upjohn Ab Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
ID27504A (id) 1998-10-01 2001-04-12 Novartis Ag Formulasi oral baru
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
FR2792527B1 (fr) 1999-04-22 2004-08-13 Ethypharm Lab Prod Ethiques Microgranules de ketoprofene, procede de preparation et compositions pharmaceutiques
US6541020B1 (en) 1999-07-09 2003-04-01 Trimeris, Inc. Methods and compositions for administration of therapeutic reagents
US6562375B1 (en) 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
JP2003508422A (ja) 1999-09-02 2003-03-04 ノストラム・ファーマスーティカルズ・インコーポレイテッド 放出制御ペレット製剤
US6544548B1 (en) 1999-09-13 2003-04-08 Keraplast Technologies, Ltd. Keratin-based powders and hydrogel for pharmaceutical applications
US6080736A (en) 1999-10-27 2000-06-27 Janus Pharmaceuticals, Inc. Methods and compositions for treating and preventing anxiety and anxiety disorders using optically pure (R) tofisopam
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
US6482439B2 (en) 1999-12-29 2002-11-19 Nanodelivery, Inc. Drug delivery system exhibiting permeability control
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
US6524621B2 (en) 2000-05-01 2003-02-25 Aeropharm Technology Inc. Core formulation
MXPA02012660A (es) 2000-06-20 2004-05-14 Atherogenics Inc 1,3-(fenilo-substituido-bis)-2-propen-1-onas y su uso para el tratamiento de padecimientos transmitidos por el vcam-1.
US6482440B2 (en) 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
ATE346929T1 (de) * 2001-02-07 2006-12-15 Ca Nat Research Council Methode zur herstellung von pflanzensamen mit verändertem fibergehalt und veränderter samenschale
US6524615B2 (en) 2001-02-21 2003-02-25 Kos Pharmaceuticals, Incorporated Controlled release pharmaceutical composition
MXPA04007719A (es) 2002-02-07 2005-09-08 Univ Missouri Compuestos 4-(3hidroxifenil) o 4-(3-alcoxifenil)-1,2,4-triazol activos del receptor opioide.
CA2495386C (en) 2002-08-14 2011-06-21 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
KR20060015482A (ko) * 2003-03-21 2006-02-17 와이어쓰 인터루킨-21/인터루킨-21 수용체의 작용제를 이용한면역장애의 치료
JP2007530703A (ja) * 2004-04-01 2007-11-01 アベンティス・ファーマスーティカルズ・インコーポレイテツド Ｍｓおよびその他の脱髄疾患を治療するためのペルオキシソーム増殖因子活性化受容体デルタアゴニストの使用
WO2006029411A2 (en) * 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
GB0424564D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
CA2667802A1 (en) * 2006-11-03 2008-05-29 Northwestern University Multiple sclerosis therapy
US20080286234A1 (en) 2007-05-15 2008-11-20 Eyink Daniel A Method for treating demyelinating diseases
JP5582535B2 (ja) 2007-06-29 2014-09-03 クラレンス ピーティーワイ エルティーディー 点眼投与による神経疾患または精神神経疾患の治療または予防
RU2010106111A (ru) 2007-07-20 2011-08-27 Стем Селл Терапьютикс Корп. (Ca) Лечение или облегчение нейровоспалительных или демиелинизирующих расстройств с помощью пролактина и иммуномодулирующего средства
US20090155207A1 (en) * 2007-11-29 2009-06-18 Hariri Robert J Use of Immunomodulatory Compounds for the Treatment of Transverse Myelitis, Multiple Sclerosis, and Other Disorders
EP2065038A1 (en) * 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) * 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
US20100160259A1 (en) 2008-12-22 2010-06-24 Robert Schmouder Dosage regimen for a s1p receptor agonist
BR112012006957A2 (pt) * 2009-09-29 2016-06-14 Novartis Ag regime de dosagem de um modulador de receptor de s1p
EP2675893B1 (en) 2011-02-18 2019-01-09 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate

Also Published As

Publication number Publication date
EP3502236A1 (en) 2019-06-26
US11246873B2 (en) 2022-02-15
US10660899B2 (en) 2020-05-26
US10493080B2 (en) 2019-12-03
US20160166687A1 (en) 2016-06-16
EP3502236B1 (en) 2023-08-23
JP2017132769A (ja) 2017-08-03
WO2012112933A1 (en) 2012-08-23
US9592288B2 (en) 2017-03-14
JP2014506583A (ja) 2014-03-17
EP2675893A1 (en) 2013-12-25
JP6133790B2 (ja) 2017-05-24
US20140038949A1 (en) 2014-02-06
ES2716865T3 (es) 2019-06-17
US20200390780A1 (en) 2020-12-17
EP2675893A4 (en) 2014-07-16
JP2020040981A (ja) 2020-03-19
US20170136029A1 (en) 2017-05-18
EP2675893B1 (en) 2019-01-09

Similar Documents

Publication Publication Date Title
DK2675893T3 (da) Dirigeret differentiering af oligodendrocyt-præcursorceller til en myeliniseringscelleskæbne
US20090203605A1 (en) Methods For Treating A Condition Characterized By Dysfunction In Protein Homeostasis
US20180171015A1 (en) Method of Increasing GIPCR Signalization in the Cells of a Scoliotic Subject
US20130302337A1 (en) Methods and compositions for treating alzheimer's disease
AU2007292883B2 (en) Treatment, prevention, and reversal of alcohol-induced brain disease
US20220090021A1 (en) In vitro human blood brain barrier
US20130309243A1 (en) Tam receptors and tam receptor ligands in detection and modulation of neuropathological disease
EP3011331B1 (en) Gi protein phosphorylation as marker for scoliosis and scoliosis progression, methods of increasing gipcr signaling in scoliotic subjects
US20160287602A1 (en) Methods for promoting motor neuron survival
US20090170899A1 (en) Stimulators of 5-HT4 receptors and uses thereof
CN109789129B (zh) 自噬改良材料及其用途
WO2008122087A1 (en) Methods for treating pervasive developmental disorders
Houff et al. Neuropharmacology of HIV/AIDS